Journal of Clinical Pediatrics >
Analysis of clinical phenotype and genotype in 171 children with Duchenne muscular dystrophy
Received date: 2021-04-26
Online published: 2022-03-09
Objective To investigate the characteristics of clinical phenotype and genotype in children with Duchenne muscular dystrophy (DMD). Methods The clinical data of 171 children diagnosed with DMD by clinical and genetic tests from January 2014 to June 2020 were collected, and the clinical manifestations and genetic variation results were analyzed. Results The median age of 171 DMD children (165 boys and 6 girls) was 4.1 (1.7-7.0) years. Among them, 21 children were younger than 1 year old, 41 children were 1-3 years old, 65 children were 3-7 years old, and 44 children were 7-13 years old. The main clinical manifestations of 171 children were motor development retardation, increased muscle enzymes and limb weakness. The first visit to the neurology department of the infants and young children was mainly due to the elevated muscle enzymes (including creatine kinase, creatine kinase isoenzyme and lactate dehydrogenase). Compared with the young children group, the infant group had a higher proportion of first visits to the neurology department due to increased muscle enzymes, and a lower proportion of visits due to motor development retardation, with statistically significant differences (P<0.05). Hormone therapy improved the condition of most children. DMD genes were mostly largely deletions (111 cases, 64.9%) by high-throughput sequencing techniques. There were 26 cases (15.2%) with large duplication variations and 34 cases (19.9%) with point variations. The variation could occur anywhere in the gene, but there were two deletion hotspots, which were located in the central exon 45-52 region (76 cases, accounting for 68.5% of the large deletion variations) and in the exon 2-28 region of 5' end (21 cases, accounting for 18.9% of the large deletion variations). Conclusions Increased muscle enzymes and limb weakness are the main clinical manifestations of DMD children, and genetic testing should be conducted in time if abnormalities are found. Understanding the clinical manifestations and genotype characteristics of DMD is very important for its prevention, management and treatment.
Key words： Duchenne muscular dystrophy; gene therapy; exon; duplication; deletion; point variation
Hongjun FANG , Sai YANG , Xiaojun KUANG , Zhi JIANG , Zhen ZHOU , Lijuan WANG , Liwen WU , Liming YANG , Shulei LIU , Hongmei LIAO . Analysis of clinical phenotype and genotype in 171 children with Duchenne muscular dystrophy[J]. Journal of Clinical Pediatrics, 2022 , 40(3) : 189 -195 . DOI: 10.12372/jcp.2022.21e0624
| [1] | Hoffman EP. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies[J]. Acta Myol, 2020, 394(4): 179-186. |
| [2] | Aslesh T, Erkut E, Yokota T. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing[J]. Expert Opin Biol Ther, 2021, 21(8): 1049-1061. |
| [3] | Ma P, Zhang S, Zhang H, et al. Comprehensive genetic characteristics of dystrophinopathies in China[J]. Orphanet J Rare Dis, 2018, 13(1): 109. |
| [4] | Kwon JB, Ettyreddy AR, Vankara A, et al. In vivo gene editing of muscle stem cells with adeno-associated viral vectors in a mouse model of Duchenne muscular dystrophy[J]. Mol Ther Methods Clin Dev, 2020, 19: 320-329. |
| [5] | Mata López S, Balog-Alvarez C, Vitha S, et al. Correction: challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy[J]. PLoS One, 2020, 15(10): e0241430. |
| [6] | Schneider AE, Aartsma-Rus A. Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy[J]. Expert Opin Biol Ther, 2021, 21(3): 343-359. |
| [7] | 胡亚美, 江载芳, 申昆玲, 等. 诸福棠实用儿科学(下册) [M]. 8版. 北京: 人民卫生出版社, 2015: 2526-2530. |
| [8] | Richards S, Aziz N, Bale S, et al. standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424. |
| [9] | Tyagi R, Arvind H, Goyal M, et al. Working memory alterations plays an essential role in developing global neuropsychological impairment in Duchenne muscular dystrophy[J]. Front Psychol, 2021, 11: 613242. |
| [10] | Hellebrekers DMJ, Vles JSH, Klinkenberg S, et al. The neurocognitive and behavioral profiles of 3 brothers with Becker muscular dystrophy [J]. Child Neurol Open, 2020, 7: 2329048X20957217. |
| [11] | Sanchez F, Weitz C, Gutierrez JM, et al. Cardiac MR imaging of muscular dystrophies[J]. Curr Probl Diagn Radiol, 2022, 51(2): 225-234. |
| [12] | Lim KRQ, Nguyen Q, Yokota T. Genotype-phenotype correlations in Duchenne and Becker muscular dystrophy patients from the Canadian neuromuscular disease registry[J]. J Pers Med, 2020, 10(4): 241. |
| [13] | Tong YR, Geng C, Guan YZ, et al. A comprehensive analysis of 2013 dystrophinopathies in China: a report from National Rare Disease Center[J]. Front Neurol, 2020, 11: 572006. |
| [14] | Juan-Mateu J, Gonzalez-Quereda L, Rodriguez MJ, et al. DMD mutations in 576 dystrophinopathy families: a step forward in genotype-phenotype correlations[J]. PLoS One, 2015, 10(8): e0135189. |
| [15] | Tawalbeh S, Samsel A, Gordish-Dressman H, et al. Comparison of serum pharmacodynamic biomarkers in prednisone-versus deflazacort-treated Duchenne muscular dystrophy boys[J]. J Pers Med, 2020, 10(4): 164. |
| [16] | Merlini L, Cecconi I, Parmeggiani A, et al. Quadriceps muscle strength in Duchenne muscular dystrophy and effect of corticosteroid treatment[J]. Acta Myol, 2020, 39(4): 200-206. |
| [17] | Sussman MD, Sienko SE, Buckon CE, et al. Efficacy of corticosteroid in decreasing scoliosis and extending time to loss of ambulation in a single clinic: an effectiveness trial[J]. J Child Orthop, 2020, 14(5): 421-432. |
| [18] | Wood CL, Hollingsworth KG, Hughes E, et al. Pubertal induction in adolescents with DMD is associated with high satisfaction, gonadotropin release and increased muscle contractile surface area[J]. Eur J Endocrinol, 2021, 184(1): 67-79. |
| [19] | Panovský R, Pešl M, Máchal J, et al. Quantitative assessment of left ventricular longitudinal function and myocardial deformation in Duchenne muscular dystrophy patients[J]. Orphanet J Rare Dis, 2021, 16(1): 57. |
| [20] | Mayer OH. The impact of corticosteroids on cardio-pulmonary progression in Duchenne muscular dystrophy[J]. Chest, 2020, 158(5): 1827-1828. |
| [21] | Santos ALYDS, Maciel FKL, Fávero FM, et al. Trunk control and upper limb function of walking and non-walking Duchenne muscular dystrophy individuals[J]. Dev Neurorehabil, 2021, 24(7): 435-441. |
| [22] | Lobo-Prat J. Enkaoua A, Rodriguez-Fernández A, et al. Evaluation of an exercise-enabling control interface for powered wheelchair users: a feasibility study with Duchenne muscular dystrophy[J]. J Neuroeng Rehabil, 2020, 17(1): 142. |
| [23] | Beckers P, Caberg JH, Dideberg V, et al. Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy[J]. Sci Rep, 2021, 11(1): 3011. |
| [24] | Ng MY, Li H, Ghelfi MD, et al. Ataluren and ami-noglycosides stimulate read-through of nonsense codons by orthogonal mechanisms[J]. Proc Natl Acad Sci U S A, 2021, 118(2): e2020599118. |
| [25] | Hanson B, Wood MJA, Roberts TC, et al. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing[J]. RNA Biol, 2021, 18(7): 1048-1062. |
| [26] | Anwar S, He M, Lim KRQ, et al. DMDA genotype-phenotype correlation study of exon skip-equivalent in-frame deletions and exon skip-amenable out-of-frame deletions across the DMD gene to simulate the effects of exon-skipping therapies: a meta-analysis[J]. J Pers Med, 2021, 11(1): 46. |
| [27] | Mendell JR, Khan N, Sha N, et al. Comparison of long-term ambulatory function in patients with Duchenne muscular dystrophy treated with eteplirsen and matched natural history controls[J]. J Neuromuscul Dis, 2021, 8(4): 469-479. |
| [28] | Scaglioni D, Catapano F, Ellis M, et al. The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy[J]. Acta Neuropathol Commun, 2021, 9(1): 7. |
| [29] | Zeng B, Zhou M, Liu B, et al. Targeted addition of mini-dystrophin into rDNA locus of Duchenne muscular dystrophy patient-derived iPSCs[J]. Biochem Biophys Res Commun, 2021, 545: 40-45. |
| [30] | Sheikh O, Yokota T. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies[J]. Expert Opin Investig Drugs, 2021, 30(2): 167-176. |
/
| 〈 |
|
〉 |
